Kim-Yip, Rebecca P.
McNulty, Ryan
Joyce, Bradley
Mollica, Antonio
Chen, Peter J. http://orcid.org/0000-0002-1094-7180
Ravisankar, Purnima
Law, Benjamin K.
Liu, David R. http://orcid.org/0000-0002-9943-7557
Toettcher, Jared E. http://orcid.org/0000-0002-1546-4030
Ivakine, Evgueni A. http://orcid.org/0000-0003-2132-4699
Posfai, Eszter http://orcid.org/0000-0002-4871-6652
Adamson, Britt http://orcid.org/0000-0002-9451-5819
Article History
Received: 14 June 2022
Accepted: 14 December 2023
First Online: 6 February 2024
Competing interests
: B.A. is an advisory board member with options for Arbor Biotechnologies and Tessera Therapeutics. B.A. holds equity in Celsius Therapeutics. D.R.L. is a consultant and equity holder of Beam Therapeutics, Prime Medicine, Pairwise Plants, Chroma Medicine, Resonance Medicine, Exo Therapeutics and Nvelop Therapeutics, companies that use genome editing or engineering. P.J.C. is currently an employee of Prime Medicine. J.E.T. is an advisor to Nereid Therapeutics and Prolific Machines. E.A.I. has pending interest in VUS Diagnostics. B.A., D.R.L. and P.J.C. are co-inventors on prime editing patent applications filed through their respective institutions. The other authors declare no competing interests.